AI Database to Tackle Global Steatotic Liver Disease Crisis

NEW YORK, NY – April 02, 2026 – In a significant move to combat a silent global health crisis, health technology firm Century Health and a leading liver disease researcher from Virginia Commonwealth University (VCU) have joined forces. The collaboration aims to build a first-of-its-kind clinical research database powered by artificial intelligence, focusing on steatotic liver disease (SLD), a condition that affects nearly 30% of the world's population.

The partnership between Century Health and Dr. Juan Pablo Arab, Director of Alcohol Sciences at VCU's prestigious Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, will create a powerful new tool to unravel the complexities of SLD. By leveraging AI to analyze vast amounts of real-world patient data, the initiative seeks to address critical gaps in understanding how the disease progresses, which could ultimately transform patient care and accelerate the development of new treatments.

The Silent Epidemic: Unraveling Steatotic Liver Disease

Steatotic liver disease is a broad term for conditions characterized by the accumulation of fat in the liver. It includes metabolic dysfunction-associated steatotic liver disease (MASLD), often linked to obesity and type 2 diabetes, and alcohol-associated liver disease (ALD). Over the past two decades, SLD has quietly become a leading cause of chronic liver disease, cirrhosis, and liver transplantation worldwide, creating a substantial public health and economic burden.

Despite its prevalence, SLD remains a medical enigma in many respects. Its progression is often silent, with many individuals unaware they have the condition until it advances to a severe, life-threatening stage. The current gold standard for diagnosing advanced forms like metabolic dysfunction-associated steatohepatitis (MASH) is a liver biopsy—an invasive, costly, and painful procedure that carries its own risks.

This diagnostic challenge is compounded by a data problem. Critical information about a patient's journey is often locked away in fragmented electronic health records (EHRs), spread across unstructured clinical notes, lab reports, and imaging files. Traditionally, researchers have relied on manual chart review to piece this information together, a painstaking and slow process that limits the scale and scope of studies. These limitations have made it incredibly difficult to understand the long-term outcomes and diverse progression patterns of SLD on a large scale, hindering the development of effective, targeted therapies.

A New Paradigm: AI Meets Real-World Clinical Data

Entering this challenging landscape is Century Health, a company specializing in applying AI to unlock the potential of real-world clinical data. The company's platform uses advanced natural language processing (NLP) and machine learning (ML) to automatically extract, structure, and curate high-quality datasets from the complex web of information within EHRs.

This technology represents a paradigm shift from traditional research methods. Instead of researchers spending months or years manually abstracting data from a few hundred records, the AI platform can process tens of thousands of records, creating a rich, longitudinal view of each patient's health over time. This high-resolution analysis of real-world disease trajectories is becoming increasingly vital for translational research and modern therapeutic development.

"Many of the most important advances in liver disease come from understanding how patients progress over time in real-world clinical settings," said Vish Srivastava, Co-Founder and CEO of Century Health. "This collaboration with Dr. Arab will set a foundation to enable critical research that can generate evidence to shape future patient care and therapeutic innovation."

The database will initially focus on key areas of interest in SLD research, including the progression of liver fibrosis (scarring), the effectiveness of non-invasive biomarkers, patterns of alcohol exposure, and major clinical outcomes. Its flexible design allows for expansion as new research questions emerge.

A Powerhouse Collaboration for Medical Breakthroughs

The collaboration's strength lies in the fusion of cutting-edge technology with deep clinical expertise. Dr. Juan Pablo Arab is a world-renowned gastroenterologist and transplant hepatologist whose work has significantly advanced the understanding of liver diseases. His role as Director of Alcohol Sciences at VCU's Stravitz-Sanyal Institute places him at the forefront of liver research.

The institute itself is a global hub for liver disease research, established following a historic $104 million gift to VCU. Its mission is to pioneer new diagnostics and treatments, making it the ideal academic partner for such an ambitious data-driven initiative. Developed under VCU's institutional research oversight, the database is intended to serve as a sustained resource for clinical and translational research for years to come.

"Steatotic liver disease is one of the most prevalent chronic liver conditions worldwide, with substantial clinical and public health impact," stated Dr. Arab. "By combining longitudinal clinical data with advanced analytics, our work with Century Health will create a powerful foundation for understanding disease progression at scale and for addressing some of the most important unanswered questions in SLD research."

Charting the Future of Research and Patient Care

The implications of this project extend far beyond a single academic study. By creating a comprehensive, extensible data resource, the partnership is building a model for how AI can compliantly accelerate medical research across a spectrum of diseases. The insights generated are expected to have a profound impact on the future of drug development for SLD.

For pharmaceutical companies and biotech firms, access to such high-quality real-world evidence can de-risk and expedite clinical trials. The database can help identify patient subgroups most likely to benefit from a new therapy, inform the design of more efficient trials, and provide evidence to support regulatory submissions. This can significantly shorten the timeline from discovery to an approved treatment reaching patients.

Of course, any project involving vast amounts of sensitive patient information raises questions about privacy and security. Both Century Health and VCU are approaching this with the highest standards. Century Health's platform is HIPAA-compliant and SOC 2-certified, employing state-of-the-art de-identification techniques and robust encryption to protect patient data. Combined with the stringent ethical oversight of VCU's Institutional Review Board (IRB), the collaboration ensures that this powerful research is conducted responsibly.

By transforming siloed, unstructured clinical records into a dynamic, analysis-ready asset, this initiative promises to generate a wave of new evidence. This fusion of artificial intelligence and clinical expertise aims to turn a flood of fragmented data into a clear path toward conquering one of the modern era's most pervasive chronic diseases.